A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury.

Although the primary outcome did not reach statistical significance, the clinically and statistically significant improvements observed in secondary measures—such as post-concussion symptoms, quality of life, anxiety, and depression—are noteworthy and provide valuable insights.

also in 111,027 other papers